Samsung Bioepis’s Eylea biosimilar Afilivu approved in KOR
By Son, Hyung-Min | translator Kim, Jung-Ju
24.02.23 16:13:12
가나다라
0
First Eylea biosimilar approved in Korea...will co-market the drug with Samil Pharm
"Will strive to address unmet medical needs in the field of ophthalmic diseases”
The approval marks the 2nd ophthalmic disease treatment Samsung Bioepis has received approval for after being granted approval for its Lucentis biosimilar Amelivu. Eylea is a macular degeneration treatment developed by the multinational pharmaceutical companies Regeneron and Bayer.
Samsung Bioepis plans to comarket both Amelivu and Afilivu with Samil Pharm. The companies released Amelivu last year and signed an agreement for Afilivu in February this year.
Samsung Bioepis conducted a Phase III clinical trial for its Eylea biosimilar in 449 patients with wet ag
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)